PH12018500642A1 - Anti-garp antibody - Google Patents
Anti-garp antibodyInfo
- Publication number
- PH12018500642A1 PH12018500642A1 PH12018500642A PH12018500642A PH12018500642A1 PH 12018500642 A1 PH12018500642 A1 PH 12018500642A1 PH 12018500642 A PH12018500642 A PH 12018500642A PH 12018500642 A PH12018500642 A PH 12018500642A PH 12018500642 A1 PH12018500642 A1 PH 12018500642A1
- Authority
- PH
- Philippines
- Prior art keywords
- antibody
- garp
- tumor
- treating
- treg
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 abstract 3
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 abstract 2
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 abstract 2
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015187488 | 2015-09-24 | ||
| PCT/JP2016/078067 WO2017051888A1 (ja) | 2015-09-24 | 2016-09-23 | 抗ｇａｒｐ抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12018500642A1 true PH12018500642A1 (en) | 2018-09-24 |
Family
ID=58386752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12018500642A PH12018500642A1 (en) | 2015-09-24 | 2018-03-22 | Anti-garp antibody |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US11046780B2 (enExample) |
| EP (3) | EP3660051A1 (enExample) |
| JP (5) | JP6878283B2 (enExample) |
| KR (2) | KR102776730B1 (enExample) |
| CN (3) | CN115869398B (enExample) |
| AU (3) | AU2016325858B2 (enExample) |
| BR (1) | BR112018005777A2 (enExample) |
| CA (1) | CA2999819A1 (enExample) |
| CO (1) | CO2018003542A2 (enExample) |
| DK (1) | DK3354729T5 (enExample) |
| ES (1) | ES2978126T3 (enExample) |
| FI (1) | FI3354729T3 (enExample) |
| HR (1) | HRP20240495T1 (enExample) |
| HU (1) | HUE066594T2 (enExample) |
| IL (3) | IL258322B2 (enExample) |
| LT (1) | LT3354729T (enExample) |
| MX (2) | MX2018003594A (enExample) |
| MY (1) | MY194586A (enExample) |
| PH (1) | PH12018500642A1 (enExample) |
| PL (1) | PL3354729T3 (enExample) |
| PT (1) | PT3354729T (enExample) |
| RS (1) | RS65415B1 (enExample) |
| RU (2) | RU2022108079A (enExample) |
| SG (2) | SG10201912570UA (enExample) |
| SI (1) | SI3354729T1 (enExample) |
| SM (1) | SMT202400160T1 (enExample) |
| TW (2) | TWI751979B (enExample) |
| WO (1) | WO2017051888A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ717476A (en) | 2013-08-01 | 2022-04-29 | Univ Catholique Louvain | Anti-garp protein and uses thereof |
| EP3932428A1 (en) | 2015-05-21 | 2022-01-05 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| CN115869398B (zh) * | 2015-09-24 | 2025-04-22 | 第一三共株式会社 | 抗garp抗体 |
| WO2017173091A1 (en) * | 2016-03-30 | 2017-10-05 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CA3026474A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| GB201707561D0 (en) * | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
| KR102376863B1 (ko) | 2017-05-12 | 2022-03-21 | 하푼 테라퓨틱스, 인크. | 메소텔린 결합 단백질 |
| CN111630070B (zh) | 2017-10-13 | 2024-07-30 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| MX2020006213A (es) | 2017-12-12 | 2020-09-14 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y metodos relacionados. |
| NZ770866A (en) * | 2018-05-31 | 2025-07-25 | Daiichi Sankyo Co Ltd | Anti-human tlr7 antibody |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| JPWO2021079958A1 (enExample) * | 2019-10-25 | 2021-04-29 | ||
| WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
| AU2021306613A1 (en) | 2020-07-07 | 2023-02-02 | BioNTech SE | Therapeutic RNA for HPV-positive cancer |
| IL303349A (en) * | 2020-12-02 | 2023-08-01 | Shanghai Henlius Biotech Inc | ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| CN117425500A (zh) | 2021-01-13 | 2024-01-19 | 纪念斯隆凯特琳癌症中心 | 抗dll3抗体-药物缀合物 |
| AU2022207708A1 (en) | 2021-01-13 | 2023-07-27 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| BR112023014319A2 (pt) * | 2021-01-18 | 2023-09-26 | Jiangxi Jemincare Group Co Ltd | Anticorpo contra a proteína garp e aplicação do mesmo |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| JP2025526336A (ja) | 2022-07-22 | 2025-08-13 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｇａｒｐ |
| KR20250120305A (ko) | 2022-12-14 | 2025-08-08 | 아스텔라스 파마 유럽 비.브이. | Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법 |
| KR20250168499A (ko) | 2023-04-07 | 2025-12-02 | 다이애고널 테라퓨틱스 인코포레이티드 | 액티빈 a 수용체 유사 유형 1(alk1)에 대한 이중 특이적 효현성 항체 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| DE69333823T2 (de) | 1992-03-24 | 2006-05-04 | Cambridge Antibody Technology Ltd., Melbourn | Verfahren zur herstellung von gliedern von spezifischen bindungspaaren |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| JPH09506508A (ja) | 1993-12-03 | 1997-06-30 | メディカル リサーチ カウンシル | 組換え結合タンパク質およびペプチド |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| JP4169478B2 (ja) | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用 |
| ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| CN1333274A (zh) * | 2000-07-07 | 2002-01-30 | 上海博德基因开发有限公司 | 一种新的多肽——人garp蛋白12.98和编码这种多肽的多核苷酸 |
| EP1331266B1 (en) | 2000-10-06 | 2017-01-04 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| RU2313368C2 (ru) | 2001-11-01 | 2007-12-27 | Ю Эй Би Рисерч Фаундейшн | Комбинации антител, обладающих селективностью по отношению к рецептору лиганда, индуцирующему апоптоз, ассоциированный с фактором некроза опухоли, и других терапевтических средств |
| NZ541458A (en) | 2003-01-07 | 2006-04-28 | Symphogen As | Method for manufacturing recombinant polyclonal proteins |
| WO2006089678A2 (en) | 2005-02-22 | 2006-08-31 | Bioinvent International Ab | Antibodies and peptides binding to hiv tat, and uses thereof |
| WO2006103639A2 (en) | 2005-03-31 | 2006-10-05 | Case Western Reserve University | Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals |
| WO2007113301A1 (en) | 2006-04-03 | 2007-10-11 | Medizinische Hochschule Hannover | Pharmaceuticals for influencing the reaction of the human immune system |
| JP2010512791A (ja) | 2006-12-22 | 2010-04-30 | シェーリング コーポレイション | Ｃｄ２００ｒに対する抗体 |
| CA2711806A1 (en) | 2008-01-11 | 2009-07-16 | Morphosys Ag | Display vectors and methods and uses thereof |
| WO2009111507A1 (en) | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 12 binding proteins |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| JP5593488B2 (ja) | 2008-11-17 | 2014-09-24 | 独立行政法人国立がん研究センター | 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療 |
| TWI480050B (zh) | 2009-02-10 | 2015-04-11 | Daiichi Sankyo Co Ltd | 抗－ｍｓｔ１ｒ抗體及其用途 |
| KR20120035145A (ko) | 2009-05-11 | 2012-04-13 | 우드라이 파마 게엠베하 | 인간화 ａｘｌ 항체 |
| TWI688395B (zh) | 2010-03-23 | 2020-03-21 | 英翠克頌公司 | 條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途 |
| MX344200B (es) | 2010-10-29 | 2016-12-08 | Daiichi Sankyo Co Ltd | Novedoso anticuerpo anti-dr5. |
| US8440797B2 (en) | 2010-12-06 | 2013-05-14 | Dainippon Sumitomo Pharma Co., Ltd. | Human monoclonal antibody |
| EP2703486B1 (en) * | 2011-04-25 | 2018-03-07 | Daiichi Sankyo Company, Limited | Anti-b7-h3 antibody |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| KR20140138215A (ko) | 2012-03-30 | 2014-12-03 | 다이이찌 산쿄 가부시키가이샤 | 신규 항 Ｓｉｇｌｅｃ-15 항체 |
| NZ631445A (en) | 2012-04-09 | 2017-02-24 | Daiichi Sankyo Co Ltd | Anti-fgfr2 antibody |
| MY166821A (en) | 2012-04-27 | 2018-07-23 | Daiichi Sankyo Co Ltd | Anti-robo4-antibody |
| JP2014141434A (ja) | 2013-01-24 | 2014-08-07 | Daiichi Sankyo Co Ltd | 抗ｒｏｂｏ４抗体 |
| FI3421486T3 (fi) * | 2012-06-22 | 2023-12-15 | Dartmouth College | Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi |
| WO2014061277A1 (ja) * | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| MX388059B (es) * | 2012-11-06 | 2025-03-19 | Scholar Rock Inc | Composiciones y metodos para modular la comunicacion celular. |
| EP2832747A1 (en) * | 2013-08-01 | 2015-02-04 | Université Catholique de Louvain | Anti-GARP protein and uses thereof |
| NZ717476A (en) * | 2013-08-01 | 2022-04-29 | Univ Catholique Louvain | Anti-garp protein and uses thereof |
| EP3253796A1 (en) | 2015-02-03 | 2017-12-13 | Université Catholique de Louvain | Anti-garp protein and uses thereof |
| CN115869398B (zh) * | 2015-09-24 | 2025-04-22 | 第一三共株式会社 | 抗garp抗体 |
| WO2017173091A1 (en) | 2016-03-30 | 2017-10-05 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination |
-
2016
- 2016-09-23 CN CN202211442176.3A patent/CN115869398B/zh active Active
- 2016-09-23 TW TW105130782A patent/TWI751979B/zh active
- 2016-09-23 PT PT168486769T patent/PT3354729T/pt unknown
- 2016-09-23 MX MX2018003594A patent/MX2018003594A/es unknown
- 2016-09-23 SG SG10201912570UA patent/SG10201912570UA/en unknown
- 2016-09-23 RU RU2022108079A patent/RU2022108079A/ru unknown
- 2016-09-23 LT LTEPPCT/JP2016/078067T patent/LT3354729T/lt unknown
- 2016-09-23 SG SG11201802352VA patent/SG11201802352VA/en unknown
- 2016-09-23 SI SI201631810T patent/SI3354729T1/sl unknown
- 2016-09-23 CN CN201911407390.3A patent/CN110922481A/zh active Pending
- 2016-09-23 FI FIEP16848676.9T patent/FI3354729T3/fi active
- 2016-09-23 EP EP19218146.9A patent/EP3660051A1/en active Pending
- 2016-09-23 EP EP24157462.3A patent/EP4349997A3/en active Pending
- 2016-09-23 HU HUE16848676A patent/HUE066594T2/hu unknown
- 2016-09-23 IL IL258322A patent/IL258322B2/en unknown
- 2016-09-23 JP JP2017540925A patent/JP6878283B2/ja active Active
- 2016-09-23 IL IL288784A patent/IL288784B2/en unknown
- 2016-09-23 MY MYPI2018000433A patent/MY194586A/en unknown
- 2016-09-23 SM SM20240160T patent/SMT202400160T1/it unknown
- 2016-09-23 CN CN201680056149.9A patent/CN108026521B/zh active Active
- 2016-09-23 EP EP16848676.9A patent/EP3354729B1/en active Active
- 2016-09-23 CA CA2999819A patent/CA2999819A1/en active Pending
- 2016-09-23 IL IL302932A patent/IL302932A/en unknown
- 2016-09-23 HR HRP20240495TT patent/HRP20240495T1/hr unknown
- 2016-09-23 RU RU2018114904A patent/RU2769379C2/ru active
- 2016-09-23 KR KR1020187008255A patent/KR102776730B1/ko active Active
- 2016-09-23 TW TW110146254A patent/TWI836305B/zh active
- 2016-09-23 DK DK16848676.9T patent/DK3354729T5/da active
- 2016-09-23 PL PL16848676.9T patent/PL3354729T3/pl unknown
- 2016-09-23 KR KR1020257006887A patent/KR20250037587A/ko active Pending
- 2016-09-23 WO PCT/JP2016/078067 patent/WO2017051888A1/ja not_active Ceased
- 2016-09-23 ES ES16848676T patent/ES2978126T3/es active Active
- 2016-09-23 AU AU2016325858A patent/AU2016325858B2/en active Active
- 2016-09-23 US US15/761,045 patent/US11046780B2/en active Active
- 2016-09-23 RS RS20240428A patent/RS65415B1/sr unknown
- 2016-09-23 BR BR112018005777-0A patent/BR112018005777A2/pt active Search and Examination
-
2018
- 2018-03-22 MX MX2023003470A patent/MX2023003470A/es unknown
- 2018-03-22 PH PH12018500642A patent/PH12018500642A1/en unknown
- 2018-04-03 CO CONC2018/0003542A patent/CO2018003542A2/es unknown
- 2018-07-24 US US16/044,196 patent/US10550198B2/en active Active
-
2020
- 2020-02-06 AU AU2020200866A patent/AU2020200866B2/en active Active
- 2020-09-29 JP JP2020164126A patent/JP6868739B2/ja active Active
-
2021
- 2021-04-28 JP JP2021075739A patent/JP7137657B2/ja active Active
- 2021-06-28 US US17/361,137 patent/US12006372B2/en active Active
-
2022
- 2022-09-02 JP JP2022140119A patent/JP2022169801A/ja active Pending
- 2022-09-14 AU AU2022231706A patent/AU2022231706B2/en active Active
-
2024
- 2024-04-30 US US18/650,725 patent/US20240360245A1/en active Pending
- 2024-12-25 JP JP2024228911A patent/JP2025036561A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500642A1 (en) | Anti-garp antibody | |
| PH12019501663A1 (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
| PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
| PH12018500097A1 (en) | Combination of pd-1 antagonist with an egfr inhibitor | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MY201148A (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
| MX383866B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| TW201613578A (en) | Pharmaceutical combinations | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| BR112017004580A2 (pt) | composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento. | |
| ZA201901367B (en) | Inhibition of olig2 activity | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| PH12018550008A1 (en) | Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse | |
| MX2016004094A (es) | Composicion farmaceutica que comprende capecitabina y ciclofosfamida. | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. | |
| MX2018015240A (es) | Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica. | |
| MA40363A (fr) | Agents de liaison de rspo1 et leurs utilisations |